Drugs / Verapamil
Verapamil
also known as
Verapamil Hydrochloride · Isoptin · verapamil ER · Verapamil HCl · verapamil HCL ER · Verapamil SR · Calan · Covera-HS · +5 more
Other / unclassified targets TXNIP via inhibition
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | CALAN SR | — | 1989-12-15 | fda.gov ↗ |
| Label expansions (2) | US (FDA) | CALAN | — | 1986-12-16 – 1988-02-23 | fda.gov ↗ |
| Approved | US (FDA) | ISOPTIN | — | 1981-08-12 | fda.gov ↗ |
Trials 80 · started per year
today
US approved 1981
1
1
2
1
9
1
4
2
3
2
3
3
2
4
1
7
1
2
5
4
6
5
2
4
4
1981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 04 trials · 1 missed | ||||||
| Phase 0 | NCT04356196 | Jun → Dec 2021 | — | Assiut University | Unknown | No outcome recorded |
| Phase 0 | NCT04790331 | Mar 2021 → Jan 2022 | — | Assiut University | Unknown | No outcome recorded |
| Phase 0 | NCT05847413 | May 2020 → Dec 2021 | type 1 diabetes mellitus | Benaroya Research Institute | Completed | Missed primary |
| Phase 0 | NCT04374500 | Jan → Oct 2006 | obesity disorder | Stefan Soderberg | Completed | No outcome recorded |
| Phase 134 trials | ||||||
| Phase 1 | NCT07796191 | Sep → Nov 2026 expected | — | Jiangsu vcare pharmaceutical technology co., LTD | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06916897 | Jan → Feb 2025 | — | Edgewise Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06354556 | Apr → May 2024 | hypertrophic cardiomyopathy | Shandong Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06118684 | Oct 2023 → Jan 2024 | chronic obstructive pulmonary disease | EpiEndo Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT06031454 | Sep → Nov 2023 | — | Guangdong Raynovent Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT05745337 | Feb → Dec 2023 | atrial fibrillation, diastolic heart failure | University of Vermont | Unknown | No outcome recorded |
| Phase 1 | NCT05304533 | Apr → Nov 2022 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT04008186 | Jun → Aug 2019 | — | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT03782662 | Nov 2018 → Mar 2019 | respiratory syncytial virus infectious disease | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT03307252 | Oct 2017 → May 2018 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02912663 | Oct 2017 → Jan 2020 | ischemic stroke | Justin Fraser | Completed | No outcome recorded |
| Phase 1 | NCT03296800 | Sep → Dec 2017 | type 2 diabetes mellitus | Theracos | Completed | No outcome recorded |
| Phase 1 | NCT03102190 | Jun 2017 → Mar 2018 | nasal cavity polyp, sinusitis | Benjamin Bleier | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03098680 | Apr 2017 → Feb 2020 | cardiovascular disorder | Cambridge University Hospitals NHS Foundation Trust | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02823106 | Aug → Sep 2016 | ischemic stroke | Justin Fraser | Withdrawn | No outcome recorded |
| Phase 1 | NCT02319148 | Jul → Oct 2014 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02111317 | Oct → Nov 2013 | — | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01873950 | May → Jul 2013 | — | Food and Drug Administration (FDA) | Completed | No outcome recorded |
| Phase 1 | NCT02235558 | Feb 2013 → Mar 2016 | ischemic stroke | Justin Fraser | Completed | No outcome recorded |
| Phase 1 | NCT01669304 | Aug 2012 → Oct 2014 | migraine disorder | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT01437384 | Sep 2011 → Mar 2012 | autoimmune thrombocytopenic purpura | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01197781 | Sep → Oct 2010 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01068847 | Feb 2010 → Oct 2012 | drug dependence | University of Arkansas | Completed | No outcome recorded |
| Phase 1 | NCT01943487 | Aug → Dec 2009 | — | Astellas Pharma Europe B.V. | Completed | No outcome recorded |
| Phase 1 | NCT00983242 | Sep → Oct 2008 | — | Mutual Pharmaceutical Company, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00733239 | Aug 2008 → Oct 2010 | opiate dependence | University of Arkansas | Completed | No outcome recorded |
| Phase 1 | NCT00707551 | Jul → Nov 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02171533 | Jun → Aug 2008 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT00593463 | Sep 2006 → May 2010 | drug dependence | University of Arkansas | Completed | No outcome recorded |
| Phase 1 | NCT00648050 | Mar 2006 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00649805 | Jan 2006 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00647673 | Jan 2006 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00648401 | Jan 2006 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT01261286 | — | Crohn disease | University of Alberta | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07199946 | Aug 2025 → Dec 2029 expected | type 1 diabetes mellitus | Johnny Ludvigsson | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03347786 | Apr 2017 → Aug 2026 overdue | ischemic stroke | Global Neurosciences Institute | Recruiting | No outcome recorded |
| Phase 1/2 | NCT01645709 | Apr 2012 → Feb 2013 | osteoarthritis, knee | Calosyn Pharma, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 211 trials | ||||||
| Phase 2 | NCT07688070 | Aug 2026 → Jul 2028 expected | cystic fibrosis, cystic fibrosis-related diabetes, glucose intolerance | Rhode Island Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07499440 | Jun 2026 → Sep 2027 expected | post-traumatic stress disorder | HB BioTech, LLC | Recruiting | No outcome recorded |
| Phase 2 | NCT06455319 | Nov 2025 → Nov 2028 expected | type 1 diabetes mellitus | University of Florida | Recruiting | No outcome recorded |
| Phase 2 | NCT06483789 | Oct 2024 → Sep 2026 | panic disorder | HB BioTech, LLC | Terminated | No outcome recorded |
| Phase 2 | NCT05593757 | Oct 2022 → Sep 2025 | ventricular fibrillation | Academic Medical Center - University of Amsterdam | Unknown | No outcome recorded |
| Phase 2 | NCT05399576 | May 2022 → May 2023 | coronary artery disorder | The First Affiliated Hospital of Zhejiang Chinese Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT04489134 | Feb 2022 → May 2023 | — | Rennes University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04545151 | Feb 2021 → Apr 2025 | type 1 diabetes mellitus | Medical University of Graz | Completed | No outcome recorded |
| Phase 2 | NCT02372253 | Feb 2015 → Dec 2017 | type 1 diabetes mellitus | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 2 | NCT01607073 | Apr 2012 → Jan 2015 | Dravet syndrome | Gillette Children's Specialty Healthcare | Completed | No outcome recorded |
| Phase 2 | NCT00706810 | Dec 2007 → Sep 2015 | brain cancer, meningioma | University of Utah | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04351763 | May 2020 → May 2021 | COVID-19 | Nicolaus Copernicus University | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00000556 | Mar 1995 → Sep 2002 | atrial fibrillation | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 3 | NCT00518947 | Nov 1994 → Jun 1999 | manic bipolar affective disorder | University of Pittsburgh | Completed | No outcome recorded |
| Phase 415 trials · 1 met primary | ||||||
| Phase 4 | NCT07445789 | Jun 2026 → Jun 2029 expected | atrial fibrillation | Martini Hospital Groningen | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04234477 | Dec 2021 → Jun 2022 | atrial fibrillation | Boston University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT04406259 | Nov 2020 → Sep 2025 overdue | cluster headache syndrome | Centre Hospitalier Universitaire de Nice | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04330300 | Apr 2020 → Jul 2021 | COVID-19, essential hypertension | National University of Ireland, Galway, Ireland | Suspended | No outcome recorded Stop: Business |
| Phase 4 | NCT04404439 | Sep 2019 → Dec 2023 | tinnitus | University of California, Irvine | Completed | No outcome recorded |
| Phase 4 | NCT03218137 | Feb 2017 → Dec 2027 expected | — | Weill Medical College of Cornell University | Recruiting | No outcome recorded |
| Phase 4 | NCT02527993 | Oct 2015 → Apr 2017 | hypoglycemia, obesity disorder | Zealand University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02454491 | May 2015 → Aug 2016 | ischemic disease | University Hospital of Ferrara | Completed | No outcome recorded |
| Phase 4 | NCT01655303 | Feb → Dec 2011 | atrial fibrillation | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT01655316 | Oct 2010 → Aug 2011 | cardiac rhythm disease | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT00348530 | Jan 2006 → Dec 2007 | cardiomyopathy, myocardial disorder, systolic heart failure | Medical University of Silesia | Unknown | No outcome recorded |
| Phase 4 | NCT00374465 | Jan 2006 → May 2008 | dilated cardiomyopathy | Medical University of Silesia | Unknown | No outcome recorded |
| Phase 4 | NCT00235001 | Jun 2004 → Nov 2006 | hypertensive disorder | Abbott | Completed | No outcome recorded |
| Phase 4 | NCT00133692 | Sep 1997 → Feb 2003 | coronary artery disorder, hypertensive disorder | University of Florida | Completed | Met primary |
| Phase 4 | NCT00413712 | Jan 1997 → Mar 2001 | — | Singapore General Hospital | Completed | No outcome recorded |
| Phase not applicable10 trials · 2 met primary | ||||||
| — | NCT07420166 | Jan → Jun 2025 | keloid | Muhammad Aamir Latif | Completed | No outcome recorded |
| — | NCT05855070 | May 2023 → May 2024 | Peyronie disease | Benha University | Unknown | No outcome recorded |
| — | NCT07866989 | Apr 2023 → Mar 2024 | chronic obstructive pulmonary disease | Ain Shams University | Completed | No outcome recorded |
| — | NCT06710600 | Sep 2022 → Apr 2024 | photosensitivity disease | Medical University of Vienna | Completed | No outcome recorded |
| — | NCT05183997 | Jan 2022 → Feb 2023 | — | Assiut University | Unknown | No outcome recorded |
| — | NCT04513509 | Oct 2020 → Jun 2022 | atrial fibrillation | National Taiwan University Hospital | Completed | No outcome recorded |
| — | NCT02454608 | May 2015 → Mar 2016 | chronic rhinosinusitis, nasal cavity polyp | Benjamin Bleier | Terminated | Met primary |
| — | NCT02248753 | Oct 2014 → Nov 2018 | atrial fibrillation | Maastricht University Medical Center | Completed | Met primary |
| — | NCT00559169 | Feb 2009 → Dec 2010 | epilepsy | University Health Network, Toronto | Withdrawn | No outcome recorded |
| — | NCT00578617 | Sep 2006 → Feb 2009 | atrial fibrillation | Mayo Clinic | Completed | No outcome recorded |
| Comparator or background therapy39 trials | ||||||
| Phase 0 | NCT05625503 Comparator | Dec 2022 → Dec 2023 | vascular disorder | University of Illinois at Chicago | Completed | No outcome recorded |
| Phase 1 | NCT03013933 Background | May 2017 → May 2022 | Hodgkins lymphoma | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT03070470 Comparator | Mar → Jun 2017 | — | Food and Drug Administration (FDA) | Completed | No outcome recorded |
| Phase 1 | NCT02653872 Comparator | Jan → Apr 2016 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01276301 Comparator | Jan → Feb 2011 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01467687 Comparator | Jul → Aug 2007 | — | Synerx Pharma, LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT01471704 Comparator | Oct → Nov 2011 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2/3 | NCT07804849 Comparator | Aug 2026 → Feb 2027 expected | type 1 diabetes mellitus | Ain Shams University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT02772354 Comparator | Apr 2016 → Sep 2017 | cardiac rhythm disease | Meshalkin Research Institute of Pathology of Circulation | Unknown | No outcome recorded |
| Phase 2/3 | NCT00804895 Background | Dec 2008 → Oct 2009 | cluster headache syndrome | Assistance Publique - Hôpitaux de Paris | Completed | Met primary |
| Phase 3 | NCT06717685 Comparator | Oct 2024 → Jan 2025 overdue | cardiac rhythm disease | Rashid Latif Medical College | Recruiting | No outcome recorded |
| Phase 3 | NCT04233034 Comparator | Jul 2020 → Sep 2022 | type 1 diabetes mellitus | Jaeb Center for Health Research | Completed | No outcome recorded |
| Phase 3 | NCT00589303 Comparator | Dec 2007 → Jul 2011 | atrial fibrillation, heart failure | Mayo Clinic | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT00313157 Comparator | Apr 2006 → Sep 2010 | atrial fibrillation | Asker & Baerum Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00679653 Comparator | Feb 2002 → Dec 2003 | hypertensive disorder, obesity disorder | Abbott | Completed | No outcome recorded |
| Phase 4 | NCT07706075 Comparator | Jan → Jul 2027 expected | atrial fibrillation | Muhammad Ali Javed | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07655440 Comparator | Jul 2026 → Jul 2031 expected | migraine disorder, tinnitus, vestibular disorder | Stanford University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06799169 Comparator | Jun 2025 → Dec 2026 expected | tinnitus | University of California, Irvine | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06897969 Comparator | Apr → Sep 2025 overdue | keloid | Nishtar Medical University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06447688 Comparator | Jun → Nov 2024 | coronary vasospasm | Mersin Medicalpark Hastanesi | Completed | No outcome recorded |
| Phase 4 | NCT06847620 Comparator | Mar → Sep 2024 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT05569382 Comparator | Aug 2022 → Apr 2027 expected | hypertrophic cardiomyopathy | Morten Steen Kvistholm Jensen | Recruiting | No outcome recorded |
| Phase 4 | NCT01996436 Comparator | Aug 2016 → Apr 2024 | intracranial vasospasm | Peng Roc Chen, MD | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01720056 Comparator | Oct 2012 → Mar 2014 | keloid | The University of Western Australia | Terminated | No outcome recorded |
| Phase 4 | NCT01675362 Comparator | Aug 2012 → Aug 2014 | nephrolithiasis | Mansoura University | Completed | No outcome recorded |
| Phase 4 | NCT00712894 Comparator | Dec 2006 → Apr 2009 | acute myocardial infarction | Fudan University | Completed | Met primary |
| Phase 4 | NCT01295047 Comparator | Jul 2006 → Dec 2007 | Marfan syndrome | Cardiff University | Completed | No outcome recorded |
| Phase 4 | NCT00234858 Comparator | Mar 2004 → Apr 2006 | hypertensive disorder, metabolic syndrome X | Abbott | Completed | No outcome recorded |
| Phase 4 | NCT00234871 Comparator | Jan 2004 → Mar 2005 | diabetes mellitus, hypertensive disorder, proteinuria | Abbott | Completed | No outcome recorded |
| Phase 4 | NCT00235014 Comparator | Mar 1997 → Jan 2006 | hypertensive disorder, type 2 diabetes mellitus | Abbott | Completed | No outcome recorded |
| — | NCT07445334 Comparator | Mar 2026 → Sep 2027 expected | ventricular tachycardia | Western Sydney Local Health District | Recruiting | No outcome recorded |
| — | NCT04573751 Comparator | Dec 2020 → Jan 2023 | ST-elevation myocardial infarction | Tomsk National Research Medical Center of the Russian Academy of Sciences | Completed | No outcome recorded |
| — | NCT04203368 Comparator | Feb → Jul 2020 | — | Ain Shams University | Completed | No outcome recorded |
| — | NCT03845010 Comparator | Feb 2019 → Jan 2023 | cardiac rhythm disease | Maatschap Cardiologie Zwolle | Completed | No outcome recorded |
| — | NCT01402427 Comparator | Mar → Aug 2011 | coronary artery disorder, poisoning | State Health Center, Hungary | Completed | No outcome recorded |
| — | NCT01126307 Comparator | Jun 2010 → Dec 2012 | epilepsy | University Health Network, Toronto | Unknown | No outcome recorded |
| — | NCT00911508 Comparator | Nov 2009 → Dec 2017 | atrial fibrillation | Mayo Clinic | Completed | No outcome recorded |
| — | NCT00684489 Comparator | Sep 2003 → Mar 2005 | essential hypertension | Medical University of South Carolina | Completed | No outcome recorded |
| — | NCT00168519 Comparator | Oct 2002 → Apr 2009 | type 2 diabetes mellitus | Baker Heart Research Institute | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-11-26 | Zydus Lifesciences Limited | Regulatory Zydus receives final approval from USFDA for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg and 240 mg zyduslife.com ↗
Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and Drug Administration (USFDA) for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg and 240 mg (USRLD: Calan SR Extended-Release Tablets, 120 mg, 180 mg and 240 mg). |
| 2020-10-16 | Zydus Lifesciences Limited | Regulatory Zydus Cadila receives final approval from USFDA for Fingolimod Capsules and Verapamil Hydrochloride Injection zyduslife.com ↗
The Company has also received the final approval from the USFDA to market Verapamil Hydrochloride Injection USP, 5 mg/2 mL (2.5 mg/mL) and 10 mg/4 mL (2.5 mg/mL), Single-Dose Vials (US RLD: Isoptin Injection). |
| 2011-05-20 | Eisai Inc. | Regulatory EISAI RECEIVES APPROVAL FOR ADDITIONAL INDICATION OF CALCIUM CHANNEL BLOCKING ANTI-ARRHYTHMIC AGENT VASOLAN® FOR PEDIATRIC PATEINTS IN JAPAN eisai.com ↗ |
| 2008-03-03 | Eisai Inc. | Regulatory Vasolan® (Ischaemic Heart Disease Treatment) Received Approval for Atrial Fibrillation/Flutter and Paroxysmal Supraventricular Tachycardia eisai.com ↗
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced today that Vasolan ® Tablets 40mg (generic name: verapamil hydrochloride) received approval for the additional indications of the treatment of atrial fibrillation/flutter and paroxysmal supraventricular tachycardia. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-11-26 | Zydus Lifesciences Limited | Zydus receives final approval from USFDA for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg and 240 mg zyduslife.com ↗ |
| 2020-10-16 | Zydus Lifesciences Limited | Zydus Cadila receives final approval from USFDA for Fingolimod Capsules and Verapamil Hydrochloride Injection zyduslife.com ↗ |
| 2011-05-20 | Eisai Inc. | EISAI RECEIVES APPROVAL FOR ADDITIONAL INDICATION OF CALCIUM CHANNEL BLOCKING ANTI-ARRHYTHMIC AGENT VASOLAN® FOR PEDIATRIC PATEINTS IN JAPAN eisai.com ↗ |
| 2008-03-03 | Eisai Inc. | Vasolan® (Ischaemic Heart Disease Treatment) Received Approval for Atrial Fibrillation/Flutter and Paroxysmal Supraventricular Tachycardia eisai.com ↗ |
Evidence & citations 18 cited values
Every value below carries the sentence it was read from. 120 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Verapamil | “Verapamil is an inhibitor of P-gp and CYP 3A4, which is frequently prescribed and recommended by FDA for drug-drug interaction studies aiming at evaluating P-gp substrates” NCT04489134 ↗116“IV beta-blockers available through the inpatient pharmacy include metoprolol or esmolol, and IV calcium channel blockers include diltiazem and verapamil.” NCT04234477 ↗ “They will receive Verapamil (Isoptin 80 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every 12 hours after ESWL for one week” NCT01675362 ↗ “For example, a dihydropyridine calcium channel blocker (verapamil or diltiazem) may be initiated if patient has concurrent asthma.” NCT07445334 ↗ “The two HB-1 doses for this study include 64/192 and 86/258 telmisartan/verapamil extended release, using unique bi-layer tablets.” NCT07499440 ↗ “Verapamil (30 mg) plus Paroxetine (4 mg) taken by mouth daily with appropriate dosage increase as necessary” NCT06799169 ↗ “Within the former group, some were assigned randomly to receive Diltiazem and some to Verapamil.” NCT00413712 ↗ “Amlodipine, diltiazem, felodipine, nicardipine, nifedipine, nimodipine, nitrendipine, verapamil” NCT04330300 ↗ “verapamil (endothelium-independent vasodilator) at 10, 30, 100 µg/min (Abbott UK Ltd)” NCT04374500 ↗ “Adenosine: 0.84 mg/kg (140 mcg/kg/minute IV for 6 minutes) Verapamil 0.15 mg/kg” NCT03218137 ↗ “Prophylactically combined intracoronary of Nicorandil and verapamil” NCT05399576 ↗ |
| Known as | Calan | “verapamil (Covera-HS, Verelan PM, Calan), reduces the strength and rate of the heart's contraction and are used in treating abnormal heart rhythms10.” NCT04356196 ↗ |
| Known as | Covera-HS | “verapamil (Covera-HS, Verelan PM, Calan), reduces the strength and rate of the heart's contraction and are used in treating abnormal heart rhythms10.” NCT04356196 ↗ |
| Known as | Isoptin | “They will receive Verapamil (Isoptin 80 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every 12 hours after ESWL for one week” NCT01675362 ↗1“Verapamil (Isoptin) (1, 3 and 6 ug.kg-1.min-1 Doses)” NCT00168519 ↗ |
| Known as | Isoptin sustained release \[SR\] | “One treatment includes the use of a calcium antagonist drug (Isoptin sustained release \[SR\] or Verapamil SR).” NCT00133692 ↗ |
| Known as | Isoptine | “Administration of a single 120 mg dose of immediate-release verapamil (Isoptine®) and a 3 mg dose of prolonged-release tacrolimus (Advagraf®)” NCT04489134 ↗ |
| Known as | Verapabene | “verapamil (Verapabene) 80mg” NCT06710600 ↗ |
| Known as | verapamil ER | “concomitant treatment with colchicine and known inhibitors of cytochrome P450 3A4 (CYP3A4)/P-glycoprotein (cyclosporine, ketoconazole, ritonavir, clarithromycin, azithromycin,...” PMID 21480191 ↗ Aug 20111“Drug: Verapamil ER” NCT02171533 ↗ |
| Known as | Verapamil HCl | “Verapamil HCl Extended-Release Capsules (300 mg; Mylan)” NCT00647673 ↗ |
| Known as | verapamil HCL ER | “extended-release verapamil hydrochloride (verapamil HCl ER).” NCT00983242 ↗1“extended release verapamil hydrochloride (verapamil HCL ER)” NCT01471704 ↗ |
| Known as | Verapamil Hydrochloride | “Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma” NCT03013933 ↗5“extended-release verapamil hydrochloride (verapamil HCl ER).” NCT00983242 ↗ “Verapamil Hydrochloride Extended-Release Capsules, 300 mg” NCT00649805 ↗ “Verapamil Hydrochloride Extended-Release Capsules, 300 mg” NCT00648050 ↗ “Drug: Verapamil Hydrochloride” NCT07706075 ↗ |
| Known as | Verapamil SR | “Eligible participants will be randomised into the Verapamil SR arm and receive instructions on frequency of administration (daily intake).” NCT04545151 ↗1“One treatment includes the use of a calcium antagonist drug (Isoptin sustained release \[SR\] or Verapamil SR).” NCT00133692 ↗ |
| Known as | Verapamil: Veralan | “Verapamil: Veralan” NCT01068847 ↗ |
| Known as | Verelan PM | “verapamil (Covera-HS, Verelan PM, Calan), reduces the strength and rate of the heart's contraction and are used in treating abnormal heart rhythms10.” NCT04356196 ↗ |
| Action | Inhibit | “calcium antagonist drug (Isoptin sustained release \[SR\] or Verapamil SR)” NCT00133692 ↗ |
| Modality | Other / unclassified | “Verapamil is a calcium channel antagonist” NCT00168519 ↗ |
| Route | Other | “infused into the femoral artery” NCT00168519 ↗ |
| Target | TXNIP | “effectively lowers beta-cell TXNIP expression” NCT02372253 ↗ |